Antibody Distribution and Dosimetry in Patients Receiving Radiolabelled Antibody Therapy for Colorectal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1989 Sep 1

PMID 2789951

Citations 14

Authors

R H Begent

J A Ledermann

A J Green

K D Bagshawe

S J Riggs

F Searle

P A Keep

T Adam

R G Dale

M G Glaser

Affiliations

Soon will be listed here.

Abstract

The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Levels of tumour and normal tissue radioactivity were measured by serial gamma-camera imaging and counting of blood and urine. Maximum concentrations were found in tumour 8 h after administration and varied up to 9-fold in different patients. Higher levels were found on average in tumour than in any other tissue. Liver, lung and blood were the other tissues in which antibody was concentrated relative to the rest of the body. Antibody cleared from all these tissues over 1 week. Second antibody directed against the antitumour (first) antibody was given 24 h after first antibody in order to accelerate clearance from the blood. This increased the tumour to blood ratio but had little effect on other tissues. Cumulative radiation dose to tumour and normal tissue was estimated. In patients with the most efficient localisation the tumour to body ratio was 20:1 and tumour to blood ratio 5:1. This may be sufficient for effective therapy of cancer in patients selected for efficient antibody localisation. The data may be used to estimate the effect of different therapeutic strategies. For instance, in the time after second antibody administration the average tumour to blood ratio of radiation dose was 11:1, suggesting that two phase systems in which the therapeutic modality is given after a good tumour to normal tissue ratio is obtained may be effective for the majority of patients.

Citing Articles

Click-to-Release: Cleavable Radioimmunoimaging with [Zr]Zr-DFO--Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio.

Vlastara M, Rossin R, Hoeben F, de Roode K, Boswinkel M, Kleijn L Theranostics. 2023; 13(12):4004-4015.

PMID: 37554267 PMC: 10405837. DOI: 10.7150/thno.84865.

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy.

Uccelli L, Martini P, Pasquali M, Boschi A Biomed Res Int. 2017; 2017:5923609.

PMID: 28951872 PMC: 5603324. DOI: 10.1155/2017/5923609.

Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.

Violet J, Dearling J, Green A, Begent R, Pedley R Br J Cancer. 2008; 99(4):632-8.

PMID: 18682714 PMC: 2527834. DOI: 10.1038/sj.bjc.6604511.

Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.

Turner J, Rose A, Glancy R, Penhale W Br J Cancer. 1998; 78(4):486-94.

PMID: 9716032 PMC: 2063083. DOI: 10.1038/bjc.1998.520.

Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment.

Kamigaki T, Yamamoto M, Ohyanagi H, Ohya M, Shimazoe T, Kono A Jpn J Cancer Res. 1995; 86(12):1216-23.

PMID: 8636013 PMC: 5920675. DOI: 10.1111/j.1349-7006.1995.tb03318.x.

References

Thomas S, Maxon H, KEREIAKES J . In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976; 03(04):253-5. DOI: 10.1118/1.594287. View

Jones D, Goldman A, Gordon I, Pritchard J, Gregory B, Kemshead J . Therapeutic application of a radiolabelled monoclonal antibody in nude mice xenografted with human neuroblastoma: tumoricidal effects and distribution studies. Int J Cancer. 1985; 35(6):715-20. DOI: 10.1002/ijc.2910350604. View

Begent R, Keep P, Green A, Searle F, Bagshawe K, Jewkes R . Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet. 1982; 2(8301):739-42. DOI: 10.1016/s0140-6736(82)90923-0. View

Rosen S, Zimmer A, Gordon L, Kazikiewicz J, Kaplan E, Variakojis D . Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol. 1987; 5(4):562-73. DOI: 10.1200/JCO.1987.5.4.562. View

Bagshawe K, Springer C, Searle F, Antoniw P, Sharma S, Melton R . A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988; 58(6):700-3. PMC: 2246864. DOI: 10.1038/bjc.1988.293. View

Ledermann J, Begent R, Bagshawe K, Riggs S, Searle F, Glaser M . Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer. 1988; 58(5):654-7. PMC: 2246821. DOI: 10.1038/bjc.1988.279. View

LENHARD Jr R, ORDER S, Spunberg J, Asbell S, Leibel S . Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol. 1985; 3(10):1296-300. DOI: 10.1200/JCO.1985.3.10.1296. View

Carrasquillo J, Krohn K, Beaumier P, McGuffin R, Brown J, Hellstrom K . Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984; 68(1):317-28. View

Harwood P, Pedley R, Boden J, Rogers G . Significance of circulatory clearance of tumour-localising IgG and F(ab')2 for potential therapy studied in a CEA-producing xenograft model. Tumour Biol. 1987; 8(1):19-25. DOI: 10.1159/000217487. View

10.

Hammond N, Moldofsky P, Beardsley M, Mulhern Jr C . External imaging techniques for quantitation of distribution of I-131 F(ab')2 fragments of monoclonal antibody in humans. Med Phys. 1984; 11(6):778-83. DOI: 10.1118/1.595580. View

11.

Chiou R, Vessella R, Limas C, Shafer R, Elson M, Arfman E . Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse model. Cancer. 1988; 61(9):1766-75. DOI: 10.1002/1097-0142(19880501)61:9<1766::aid-cncr2820610908>3.0.co;2-b. View

12.

ORDER S, Stillwagon G, Klein J, Leichner P, Siegelman S, Fishman E . Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol. 1985; 3(12):1573-82. DOI: 10.1200/JCO.1985.3.12.1573. View

13.

Raso V . Antibody mediated delivery of toxic molecules to antigen bearing target cells. Immunol Rev. 1982; 62:93-117. DOI: 10.1111/j.1600-065x.1982.tb00391.x. View

14.

Zalcberg J, Thompson C, Lichtenstein M, McKenzie I . Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies. J Natl Cancer Inst. 1984; 72(3):697-704. View

15.

Lee Y, Bullard D, Zalutsky M, Coleman R, Wikstrand C, Friedman H . Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res. 1988; 48(3):559-66. View

16.

Wakabayashi S, Okamoto S, Taniguchi M . Anti-tumor effects of radiolabeled syngeneic monoclonal anti-melanoma antibodies. Gan. 1984; 75(8):707-13. View

17.

Goldenberg D, Gaffar S, Bennett S, Beach J . Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res. 1981; 41(11 Pt 1):4354-60. View

18.

Mach J, Carrel S, Forni M, Ritschard J, Donath A, Alberto P . Tumor localization of radio-labeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med. 1980; 303(1):5-10. DOI: 10.1056/NEJM198007033030102. View

19.

Leichner P, Klein J, Fishman E, Siegelman S, Ettinger D, ORDER S . Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers. Cancer Drug Deliv. 1984; 1(4):321-8. DOI: 10.1089/cdd.1984.1.321. View

20.

Badger C, Krohn K, Shulman H, Flournoy N, Bernstein I . Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies. Cancer Res. 1986; 46(12 Pt 1):6223-8. View